Skip to content
CFEDSC
  • Home
  • About CFEDSC
  • About Cystic Fibrosis
  • Research Posts
    • Research Reports
    • Abstracts
    • Full Length Papers
    • Clinical Trial Reports
  • About Our Team
  • Legal Information
  • Submit a Paper

Clinical Trial Report P-1037

March 23, 2023September 18, 2015 by Cystic Fibrosis Educational Services

Clinical Trial Report P-1037

Categories Clinical Trial Reports Tags Clinical Trial Reports
Clinical Trial Report: P-1037
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
« Previous Post
Next Post »

Quick Links

  • Research Pipeline
  • Clinical Trials
  • Legal Help & Medical Insurance
  • CF Services Pharmacy

Current News and Events

  • CFTR Modulation Research funded by CFFOctober 4, 2017
  • Interim Data from Clinical Trial Support MS1819 as Potential Therapy for EPI in CF PatientsOctober 2, 2017
  • Enrollment Underway in CF Clinical Trial for Ear Toxicity Caused by AntibioticsOctober 2, 2017
  • ProQR’s Inhaled RNA Therapy Improves CF Symptoms in Phase 1 Clinical TrialOctober 2, 2017
  • CF Patient, Recovering from Double Transplant, Inspires ‘Lunges4Lungs’ FundraiserSeptember 29, 2017
  • Vizient Awards Alcresta Contract for Relizorb, Which Helps CF Patients Digest Healthy FatsSeptember 29, 2017
  • What’s Next for the CF Community and Health Care ReformSeptember 7, 2017
Copyright © 2023 - Cystic Fibrosis Educational Services | Powered By: Thump Local